Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

7

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

5-hydroxytryptamine receptor 1B

7

5-hydroxytryptamine receptor 1D

7

5-hydroxytryptamine receptor 1F

7

Muscarinic acetylcholine receptor M2

3

Muscarinic acetylcholine receptor M3

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

10

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2002

7

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Migraine

7

Glaucoma

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

10

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

10

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

7

Rubitsov, M.V.|Muklina, E.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

10

FDA UNII

10

PUBCHEM

10

EPA CompTox

5

NCI_THESAURUS

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANALGESICS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIGLAUCOMA PREPARATIONS AND MIOTICS

1

ANTIMIGRAINE PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Parasympathomimetics

1

Selective serotonin (5HT1) agonists

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

8

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ELETRIPTAN

22QOO9B8KI

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ACECLIDINE

0578K3ELIO

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Conditions:

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate ...

(cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

ELETRIPTAN SUCCINATE

92AD31CQ59

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ELETRIPTAN MESYLATE

607KP935Y1

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ELETRIPTAN HYDROCHLORIDE

OL4Q27AUZF

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ELETRIPTAN HYDROBROMIDE MONOHYDRATE

4139X692FA

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ELETRIPTAN HYDROBROMIDE

M41W832TA3

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ELETRIPTAN HEMISULFATE

AMM8PSU28B

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2002

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1B

5-hydroxytryptamine receptor 1D

Conditions:

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affin...

ity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

ACECLIDINE HYDROCHLORIDE

3B22O325Q6

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Conditions:

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate ...

(cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

ACECLIDINE SALICYLATE

MCC2GG434J

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M3

Conditions:

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate ...

(cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1